1996> 1997 1998> 1999> 2000> 2001>

 
The National AIDS Treatment Advocacy Project - NATAP - provides the latest in HIV and AIDS drug research and treatment information as well as comprehensive reports and developments from the Fifth Retroviruses and Opportunistic Infections conference, as well as from the ICAR, ICAAC, IDSA, European and International HIV and AIDS conferences, and from other sources. 

     1997

REPORTS FROM IDSA and ICAAC CONFERENCES, THE FDA, and OTHER SOURCES

pdf
pdf
pdf
pdf
pdf
pdf

pdf

Post 4th Retroviruses Conference Reports

 
pdf
pdf
pdf
pdf
pdf
  • 1592U89: Cross-Resistance With Nucleosides and Expanded Access and CNS Penetration in Animal Models (7/29/97)
pdf
pdf
Reports from FDA, ICAR, and other sources  
  • FDA Proposal: Using Viral Load in AIDS Clinical Trials (5/25/97)
pdf
pdf
pdf
pdf
  • PMPA: first human data (5/3/97)
pdf
pdf
pdf
pdf
pdf
pdf
pdf
  • Nelfinavir (modified 4/29/97) general information, study results (CD4 and viral load), dosing schedule, eating instructions, drug interactions, combination with other protease inhibitors and NNRTIs, side effects, resistance, cross-resistance
pdf

pdf

pdf

pdf
pdf
  • Altis I & II: a pilot open label study of d4T/3TC in treatment-naive and experienced individuals (3/9/97)
pdf

pdf

pdf

pdf
pdf
  • DMP-266: an NNRTI; early safety and efficacy data (modified 1/31/97)
pdf

POST BIRMINGHAM CONFERENCE REPORTS

 
pdf
pdf
pdf
pdf
pdf

Daily Highlights from Geneva (1997)
written by Jules Levin

1996> 1997 1998> 1999> 2000> 2001>